文献速递脑血管病

大缺血性卒中患者血管内取栓的成本效益

Cost-Effectiveness of Endovascular Thrombectomy in Patients with Large Ischemic Stroke.
PubMed 文献 · Ann Neurol · 2024-10-31

本研究基于SELECT2试验数据,采用7状态Markov模型,从美国、澳大利亚和西班牙社会视角分析大缺血性卒中患者血管内取栓的成本效益。结果显示取栓可改善健康结局并降低社会成本,平均组间差异为1.24质量调整生命年,在美国、澳大利亚和西班牙分别节省23,409美元、10,691美元和30,036美元。亚组分析显示老年(≥70岁)和更严重卒中(NIHSS≥20)患者中成本效益仍保留。

要点

  • 大缺血性卒中患者取栓可改善健康结局并降低社会成本。
  • 平均组间差异为1.24质量调整生命年,美国节省23,409美元。
  • 老年(≥70岁)和更严重卒中(NIHSS≥20)患者中成本效益仍保留。

核心结论

  • 在美国、澳大利亚和西班牙不同环境中,大核心梗死患者取栓均显示成本效益,包括老年和更严重卒中患者。

研究设计与样本

  • 基于模型的成本效益分析,采用7状态Markov模型,各状态由改良Rankin量表评分定义,从美国、澳大利亚和西班牙社会视角开展。
  • 初始3个月概率来自SELECT2试验,其他模型输入包括转移概率、医疗和非医疗成本及效用权重均来自已发表文献和政府网站。
  • 分析包括广泛的敏感性和亚组分析。

主要发现

  • 取栓改善健康结局,从社会视角看与更低成本相关。
  • 取栓具有成本效益,平均组间差异为1.24质量调整生命年,在美国节省23,409美元,澳大利亚节省10,691美元,西班牙节省30,036美元,此外还有患者和照护者生产力方面的未计价收益。
  • 亚组分析与总体人群方向一致,老年(≥70岁)和更严重卒中(NIHSS≥20)患者中成本效益仍保留。
  • 敏感性分析大体与基础案例结果一致。

临床怎么用

  • 结果进一步支持调整医疗系统以适应取栓适应证扩展至大核心梗死患者,最大化取栓获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Whereas highly cost-effective and cost-saving for patients with small infarcts, whether endovascular thrombectomy (EVT) remains cost-effective in patients with extensive ischemic injury is uncertain. METHODS: We conducted a model-based cost-effectiveness analysis from the United States, Australian, and Spanish societal perspectives, using a 7-state Markov model, with each state defined by the modified Rankin Scale (mRS) score. Initial probabilities at 3 months were derived from the SELECT2 trial. All other model inputs, including transition probabilities, health care and non-health care costs, and utility weights, were sourced from published literature and government websites. Our analysis included extensive sensitivity and subgroup analyses. RESULTS: EVT in patients with large ischemic stroke improved health outcomes and was associated with lower costs from a societal viewpoint. EVT was cost-effective with a mean between-group difference of 1.24 quality-adjusted life years (QALYs), and a cost-saving of $23,409 in the United States, $10,691 in Australia, and $30,036 in Spain, in addition to uncosted benefits in productivity for patients and carers. Subgroup analyses were directionally consistent with the overall population, notably with preserved cost-effectiveness in older patients (≥ 70 years) and those with more severe strokes (National Institutes of Health Stroke Scale [NIHSS] ≥ 20). Sensitivity analyses were largely consistent with the base-case results. INTERPRETATION: EVT demonstrated cost-effectiveness in patients with large core across different settings in the United States, Australia, and Spain, including older patients and those with more severe strokes. These results further support adaptation of systems of care to accommodate the expansion of thrombectomy eligibility to patients with large cores and maximize EVT benefits. ANN NEUROL 2025;97:222-231.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Gao L, Churilov L, Johns H, et al. Cost-Effectiveness of Endovascular Thrombectomy in Patients with Large Ischemic Stroke. Ann Neurol. 2024. PMID: 39479933. doi:10.1002/ana.27119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。